[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Double-Blind; Randomized; Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer Type of group;1 N\u00b0 of participants:146 sujetos Intervention(s) description:The investigational product in this study will be TL-895 (formerly M7583). TL-895 will be used in both Part 1 and Part 2 of the study. The dose in Part 1 will start at the 200 mg BID dose followed by 150 mg and 100 mg BID; as needed; depending on DLT at each dose level. The Phase 2 dose will be the RP2D from Part 1. TL-895 is supplied as film-coated tablets and available at strengths of 50 mg (with excipients).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1296, "treatment_name": "Tl-895", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Double-Blind; Randomized; Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer Type of group;1 N\u00b0 of participants:146 sujetos Intervention(s) description:The investigational product in this study will be TL-895 (formerly M7583). TL-895 will be used in both Part 1 and Part 2 of the study. The dose in Part 1 will start at the 200 mg BID dose followed by 150 mg and 100 mg BID; as needed; depending on DLT at each dose level. The Phase 2 dose will be the RP2D from Part 1. TL-895 is supplied as film-coated tablets and available at strengths of 50 mg (with excipients).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]